Challenges in achieving the guideline-recommended amikacin level for <i>Mycobacterium avium</i> complex pulmonary disease.

ABSTRACT:

Background

The addition of aminoglycosides to a macrolide-based regimen is recommended for refractory Mycobacterium avium complex pulmonary disease (MAC-PD). For intravenous amikacin (AMK) administration three times a week, the ATS/ERS/ESCMID/IDSA guidelines recommend targeting a peak serum concentration of 65-80 µg/mL. However, the feasibility of achieving the guideline-recommended AMK concentration remains unclear.

Methods

From 2018 to 2022, we retrospectively analyzed patients with refractory MAC-PD treated with AMK thrice weekly for ≥3 months combined with an oral regimen of ≥2 drugs, including macrolides. The peak serum concentration and therapeutic effects of AMK were evaluated.

Results

The median age of the 9 patients was 70 years (range: 50-79 years; 2

SUBMITTER: Akutsu T 

PROVIDER: S-EPMC11874810 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature